RxDoctor Payments Data

Tirth Shah, MD

Ophthalmology · Athens, GANPI 1407417363

Payments from drug & device makers

$2,130in general payments, 2019–2025

Across 79 payments — averaging $26.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$592
  • Sight Sciences, Inc.$236
  • AbbVie$221
  • Bausch & Lomb Americas Inc.$192
  • Tarsus Pharmaceuticals, Inc.$151
  • Sun Pharmaceutical Industries Inc.$140
  • plus $599 from 11 others

What the payments were for

  • Food & beverage$2,11699%
  • Entertainment$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,130 in reported general payments places this provider in the 50th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$169,994
Medicare patients
396
Services billed
1,714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine33$34,226
IlevroNepafenac49$18,017
LumiganBimatoprost16$8,925
Prednisolone Acetate121$4,790
Cyclosporine11$4,627
Latanoprost152$2,867
Fluorometholone33$2,420
Travoprost11$2,326
Brimonidine Tartrate19$1,375
Ketorolac Tromethamine44$1,019
ValacyclovirValacyclovir Hcl14$946
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat59$821
Ciprofloxacin Hcl85$818
MoxifloxacinMoxifloxacin Hcl17$593
Timolol Maleate41$479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$221$43,15149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →